The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [0.03%]
达格列净对有或无2型糖尿病的慢性肾脏病患者肾功能下降速率的影响：DAPA-CKD试验的预设分析
Hiddo J L Heerspink,Niels Jongs,Glenn M Chertow et al.
Hiddo J L Heerspink et al.
Background: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagl...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Nov;9(11):743-754. DOI:10.1016/S2213-8587(21)00242-4 2021
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial [0.03%]
在DAPA-CKD试验期间通过尿蛋白和eGFR斜率预测治疗反应
Katherine R Tuttle
Katherine R Tuttle
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [0.03%]
达格列净对伴有或不伴有2型糖尿病的慢性肾病患者尿白蛋白排泄的影响：DAPA-CKD试验的预设分析
Niels Jongs,Tom Greene,Glenn M Chertow et al.
Niels Jongs et al.
Background: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients ...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2021 Nov;9(11):755-766. DOI:10.1016/S2213-8587(21)00243-6 2021
Charlotte Steenblock,Peter E H Schwarz,Barbara Ludwig et al.
Charlotte Steenblock et al.
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction ...
Bart Van der Schueren,Darcy Ellis,Raquel N Faradji et al.
Bart Van der Schueren et al.
Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hy...
Statins for Graves' orbitopathy: a new tool for prevention and treatment? [0.03%]
他汀类药物治疗格雷夫眼病：一个新的预防和治疗方法？
Luigi Bartalena,Eliana Piantanida,Maria Laura Tanda
Luigi Bartalena
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial [0.03%]
他汀类药物治疗格雷夫眼病（STAGO）：一项二期、无盲法、适应性、单中心随机临床试验
Giulia Lanzolla,Elena Sabini,Marenza Leo et al.
Giulia Lanzolla et al.
Background: A protective action of statins on development of Graves' orbitopathy suggests that statins might be used for treatment of the disease. We aimed to assess the efficacy of the addition of a statin, atorvastatin,...
Impact of the COVID-19 pandemic on transgender and gender diverse health care [0.03%]
COVID-19大流行对跨性别和性别多样化医疗保健的影响
Claire M Burgess,Abagail W Batchelder,Colleen A Sloan et al.
Claire M Burgess et al.